Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of C. difficile Toxoid Vaccine in Healthy Japanese Adults
NCT01896830Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2013
- Primary completion
- Oct 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ACAM-CDIFF in Clostridium difficile infection (CDI), sponsored by Sanofi. Started Jul 2013; status: completed.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01896830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896830.